Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has received an average rating of “Hold” from the thirteen analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and four have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $33.67.
Several brokerages have recently commented on VNDA. BidaskClub downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, January 24th. ValuEngine downgraded Vanda Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, February 4th. Cantor Fitzgerald downgraded Vanda Pharmaceuticals from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $38.00 to $30.00 in a report on Wednesday, February 6th. Stifel Nicolaus reissued a “buy” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, February 6th. Finally, Oppenheimer reduced their target price on Vanda Pharmaceuticals from $29.00 to $21.00 in a report on Thursday, February 14th.
In related news, CFO James Patrick Kelly sold 4,976 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $20.15, for a total value of $100,266.40. Following the completion of the transaction, the chief financial officer now owns 218,497 shares in the company, valued at approximately $4,402,714.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Mihael Hristos Polymeropoulos sold 38,166 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $19.41, for a total transaction of $740,802.06. Following the completion of the transaction, the chief executive officer now owns 1,217,136 shares of the company’s stock, valued at approximately $23,624,609.76. The disclosure for this sale can be found here. Insiders sold a total of 59,274 shares of company stock worth $1,164,127 over the last three months. 8.20% of the stock is owned by company insiders.
Shares of VNDA traded up $0.23 on Thursday, hitting $16.35. The company’s stock had a trading volume of 513,081 shares, compared to its average volume of 853,177. The company has a market capitalization of $853.78 million, a P/E ratio of 34.06, a PEG ratio of 10.96 and a beta of 0.44. Vanda Pharmaceuticals has a fifty-two week low of $13.66 and a fifty-two week high of $33.44.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.08). The business had revenue of $47.71 million during the quarter, compared to analyst estimates of $51.74 million. Vanda Pharmaceuticals had a return on equity of 8.07% and a net margin of 10.92%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.14 earnings per share. Sell-side analysts anticipate that Vanda Pharmaceuticals will post 0.1 EPS for the current fiscal year.
Vanda Pharmaceuticals Company Profile
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
Recommended Story: Price to Earnings Ratio (PE)
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.